Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Biolase (BIOL)
NASDAQ:BIOL
Biolase (BIOL) Stock Price & Analysis
1,608 Followers
BIOL Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.13 - $17.50
Previous Close$0.16
Volume4.84M
Average Volume (3M)5.40M
Market Cap
$5.31M
Enterprise Value$13.47M
Total Cash (Recent Filing)$6.39M
Total Debt (Recent Filing)$14.55M
Price to Earnings (P/E)>-0.1
Beta0.59
Next Earnings
Aug 08, 2024EPS Estimate
-$0.08Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-20.55
Shares Outstanding33,394,979
10 Day Avg. Volume3,089,077
30 Day Avg. Volume5,400,561
Standard Deviation0.33
R-Squared0.01
Alpha-0.11
Financial Highlights & Ratios
Price to Book (P/B)-1.09
Price to Sales (P/S)0.51
Price to Cash Flow (P/CF)-0.20
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue0.30
Enterprise Value/Gross Profit0.85
Enterprise Value/Ebitda-0.62
Forecast
1Y Price Target
$2.20Price Target Upside1283.65% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
Biolase News
PremiumCompany Announcements
Biolase Announces Common Stock Shares Update
PremiumCompany Announcements
Biolase Raises $7 Million, Expands Capital and Ensures Compliance
Bulls Say, Bears Say
Bulls Say
Financial EfficiencyBIOL now manufactures all of its required trunk fiber in-house, which should decrease material costs and support margin improvement.
Market PositionThe company's strong dentist retention rate indicates market acceptance and product efficacy, reinforcing a positive outlook.
Product DevelopmentThe launch of the Waterlase iPlus Premier Edition provides a more accessible price point, potentially boosting future sales.
Bears Say
Capital ConcernsBased on BIOL's cash position and financial forecasts, the company will need to execute a potentially dilutive capital raise.
Negative EarningsGAAP loss per share was significantly wider than consensus and estimate.
Regulatory ConcernsBased on continued non-compliance with listing requirements, BIOL is downgraded to Hold, from Buy.
---
Ownership Overview
50.80%
Insiders
0.06% Mutual Funds
0.09% Other Institutional Investors
49.06% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
BIOL FAQ
What was Biolase’s price range in the past 12 months?
Biolase lowest stock price was $0.13 and its highest was $17.50 in the past 12 months.
What is Biolase’s market cap?
Currently, no data Available
When is Biolase’s upcoming earnings report date?
Biolase’s upcoming earnings report date is Aug 08, 2024 which is in 80 days.
How were Biolase’s earnings last quarter?
Biolase released its earnings results on May 13, 2024. The company reported -$0.36 earnings per share for the quarter, missing the consensus estimate of -$0.17 by -$0.19.
Is Biolase overvalued?
According to Wall Street analysts Biolase’s price is currently Undervalued.
Does Biolase pay dividends?
Biolase does not currently pay dividends.
What is Biolase’s EPS estimate?
Biolase’s EPS estimate is -$0.08.
How many shares outstanding does Biolase have?
Biolase has 33,394,978 shares outstanding.
What happened to Biolase’s price movement after its last earnings report?
Biolase reported an EPS of -$0.36 in its last earnings report, missing expectations of -$0.17. Following the earnings report the stock price went down -16.667%.
Which hedge fund is a major shareholder of Biolase?
Currently, no hedge funds are holding shares in BIOL
---
Biolase Stock Smart Score
Not Ranked
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$2.20 (1283.65% Upside)
$2.20 (1283.65% Upside)
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.4%
Last 30 Days ▼ 2.8%
Last 30 Days ▼ 2.8%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-99.05%
12-Months-Change
Fundamentals
Return on Equity
-683.42%
Trailing 12-Months
Asset Growth
-18.10%
Trailing 12-Months
Company Description
Biolase
BIOLASE, Inc. is a medical device company, which engages in the development, manufacture, market and sale of laser systems in dentistry and medicine. It operates through Waterlase (all-tissue) systems, and Diode (soft-tissue) systems products. The Waterlase systems uses a patented combination of water and laser energy to perform procedures using drills, scalpels, and other traditional dental instruments for cutting soft and hard tissue. The Diode systems performs soft tissue, pain therapy, and cosmetic procedures, including teeth whitening. The company was founded in 1987 and is headquartered in Irvine, CA.
---
BIOL Earnings Call
Q1 2024
0:00 / 0:00
---
BIOL Stock 12 Month Forecast
Average Price Target
$2.20
▲(1283.65% Upside)
Technical Analysis
Best Analysts Covering BIOL
1 Year
1 Year Success Rate
1/13 ratings generated profit
1 Year Average Return
-68.42%
reiterated a buy rating 2 months ago
Copying Edward Woo's trades and holding each position for 1 Year would result in 7.69% of your transactions generating a profit, with an average return of -68.42% per trade.
---